Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
OXFORD, United Kingdom and MARLBOROUGH, Mass., 2016-04-20 17:03 CEST (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC(Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and (484) 365-2897 for international callers and reference confirmation code 89843505, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website atwww.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TBtest, which is used to test for tuberculosis infection. The T-SPOT.TBtest has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMVtest and the T-SPOT.PRTtest are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and theOxford Immunoteclogo are trademarks ofOxford Immunotec Ltd.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0500
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Corel26.9.2018 15:01 | pressemeddelelse
MindManager 2019 Empowers Professionals and Teams to Uncover Possibilities, Unite People, and Unleash Productivity
Crown Bioscience26.9.2018 14:01 | pressemeddelelse
CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models
XBiotech Inc.26.9.2018 14:01 | pressemeddelelse
XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases
Juniper Systems Limited26.9.2018 06:37 | pressemeddelelse
Juniper Systems Unveils New Cedar CP3 Rugged Smartphone
IASLC25.9.2018 19:27 | pressemeddelelse
World Conference on Lung Cancer Tuesday Press Conference: Improving the Cure Rate for Stage III Lung Cancer
Northwest Analytics25.9.2018 15:08 | pressemeddelelse
Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum